Autologous mesenchymal stem cell therapy for progressive …

Posted: August 3, 2015 at 3:47 pm

Nath U, Ben-Shlomo Y, Thomson RG, Morris HR, Wood NW, Lees AJ, Burn DJ: The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK.

Brain 2001, 124:1438-1449.

Bower JH, Maraganore DM, McDonnell SK, Rocca WA: Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990.

Neurology 1997, 49:1284-1288.

Ludolph AC, et al.: Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers and treatment options.

Eur J Neurol 2009, 16:297-309.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Neurology 1996, 47:1-9.

Litvan I, Campbell G, Mangone CA, Verny M, McKee A, Chaudhuri KR, Jellinger K, Pearce RK, DOlhaberriague L: Which clinical features differentiate progressive supranuclear palsy (SteeleRichardsonOlszewski syndrome) from related disorders? A clinicopathological study.

Brain 1997, 120:65-74.

Continued here:
Autologous mesenchymal stem cell therapy for progressive ...

Related Posts